Patents by Inventor H. Marie Loughran

H. Marie Loughran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240076291
    Abstract: The present invention relates to compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).
    Type: Application
    Filed: November 18, 2021
    Publication date: March 7, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Michael J. Breslin, Mark E. Fraley, H. Marie Loughran, James J. Mulhearn, Anthony J. Roecker, Kathy M. Schirripa, Shawn J. Stachel
  • Publication number: 20240018140
    Abstract: The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).
    Type: Application
    Filed: September 15, 2021
    Publication date: January 18, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Melissa C. Ford, Mark E. Fraley, Kristen L.G. Jones, H. Marie Loughran, James J. Mulhearn, Anthony J. Roecker, Kathy M. Schirripa, Ling Tong
  • Patent number: 11472776
    Abstract: Novel quinazolinones useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said compounds, processes for the preparation of said compounds, intermediates used in the preparation of said compounds, and pharmaceutical compositions containing said compounds. The invention further relates to methods of use of said compounds, salts of said compounds, and said compositions in treating neurodegenerative diseases and related conditions.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: October 18, 2022
    Assignee: Oligomerix, Inc.
    Inventors: Eliot J. Davidowitz, James G. Moe, Allen B. Reitz, Haiyan Bian, Charles Gluchowski, James Hendrix, Albert S. Yehaskel, Mark E. McDonnell, H. Marie Loughran
  • Patent number: 11306075
    Abstract: Novel benzofurans, benzothiophenes and indoles useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said compounds, processes for the preparation of said compounds, intermediates used in the preparation of said compounds, and pharmaceutical compositions containing said compounds. The invention further relates to methods of use of said compounds, salts of said compounds, and said compositions in treating neurodegenerative diseases and related conditions.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: April 19, 2022
    Assignee: Oligomerix, Inc.
    Inventors: Eliot J. Davidowitz, James G. Moe, Allen B. Reitz, Haiyan Bian, Charles Gluchowski, James Hendrix, Albert S. Yehaskel, Mark E. McDonnell, H. Marie Loughran
  • Patent number: 10780084
    Abstract: The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: September 22, 2020
    Assignees: YALE UNIVERSITY, KLEO PHARMACEUTICALS, INC.
    Inventors: David Spiegel, H. Marie Loughran, Jeffrey C. Pelletier, Allen B. Reitz, Matthew Ernest Welsch
  • Publication number: 20190192497
    Abstract: The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells.
    Type: Application
    Filed: August 3, 2017
    Publication date: June 27, 2019
    Inventors: David Spiegel, H. Marie Loughran, Jeffrey C. Pelletier, Allen B. Reitz, Matthew Ernest Welsch
  • Patent number: 10160756
    Abstract: The present invention includes compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and/or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: December 25, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Ronald N. Harty, Bruce D. Freedman, Jay E. Wrobel, Allen B. Reitz, H. Marie Loughran
  • Patent number: 10138255
    Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: November 27, 2018
    Assignees: Merck Sharp & Dohme Corp., MSD R&D (China) Co., Ltd.
    Inventors: Peter D. Williams, John A. McCauley, Christopher J. Bungard, David Jonathan Bennett, Sherman T. Waddell, Gregori J. Morriello, Lehua Chang, Michael P. Dwyer, M. Katharine Holloway, Alejandro Crespo, Xin-Jie Chu, Catherine Wiscount, H. Marie Loughran, Jesse J. Manikowski, Jurgen Schulz, Kartik M. Keertikar, Bin Hu, Bin Zhong, Tao Ji
  • Patent number: 9840478
    Abstract: The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: December 12, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter D. Williams, John A. McCauley, David Jonathan Bennett, Christopher J. Bungard, Lehua Chang, Michael P. Dwyer, M. Katharine Holloway, Kartik M. Keertikar, H. Marie Loughran, Jessie J. Manikowski, Gregori J. Morriello, Dong-Ming Shen, Edward C. Sherer, Jurgen Schultz, Sherman T. Waddell, Catherine M. Wiscount, Nicolas Zorn, Xin-Jie Chu, Satyanarayana Tummanapalli, Vijayasaradhi Sivalenka, Bin Hu, Tao Ji, Bin Zhong
  • Publication number: 20170174678
    Abstract: The present invention includes bicyclic compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and/or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.
    Type: Application
    Filed: March 31, 2015
    Publication date: June 22, 2017
    Inventors: Ronald N. HARTY, Bruce D. FREEDMAN, Jay E. WROBEL, Allen B. REITZ, H. Marie LOUGHRAN
  • Publication number: 20170073354
    Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.
    Type: Application
    Filed: March 6, 2015
    Publication date: March 16, 2017
    Applicants: Merck Sharp & Dohme Corp., MSD R&D (China) Co., Ltd.
    Inventors: Peter D. Williams, John A. McCauley, Christopher J. Bungard, David Jonathan Bennett, Sherman T. Waddell, Gregori J. Morriello, Lehua Chang, Michael P. Dwyer, M. Katharine Holloway, Alejandro Crespo, Xin-Jie Chu, Catherine Wiscount, H. Marie Loughran, Jesse J. Manikowski, Jurgen Schulz, Kartik M. Keertikar, Bin Hu, Bin Zhong, Tao Ji
  • Publication number: 20160159752
    Abstract: The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.
    Type: Application
    Filed: July 29, 2014
    Publication date: June 9, 2016
    Applicants: Merck Sharp & Dohme Corp., MSD R&D (CHINA) CO., LTD.
    Inventors: Peter D. Williams, John A. McCauley, David Jonathan Bennett, Christopher J. Bungard, Lehua Chang, Michael P. Dwyer, M. Katharine Holloway, Kartik M. Keertikar, H. Marie Loughran, Jessie J. Manikowski, Gregori J. Morriello, Dong-Ming Shen, Edward C. Sherer, Jurgen Schultz, Sherman T. Waddell, Catherine M. Wiscount, Nicolas Zorn, Xin-Jie Chu, Satyanarayana Tummanapalli, Vijayasaradhi Sivalenka, Bin Hu, Tao Ji, Bin Zhong
  • Publication number: 20120022045
    Abstract: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: the asterisk * in Q denotes the point of attachment to the rest of the compound; and n, L1, L2, X1, X2, ?3, Y, Z, R1, R2 and R3 are defined herein. The N compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: January 25, 2010
    Publication date: January 26, 2012
    Inventors: Shankar Venkatraman, John S. Wai, Wayne Thompson, Boyoung Kim, Richard C.A. Isaacs, H. Marie Loughran, Dai-Shi Su, John Lim, Mark W. Embrey, Peter D. Williams